|
|
Analysis of Selected Determinants of Drug Policy in the Czech Republic
Kostřiba, Jan ; Vlček, Jiří (advisor) ; Foltán, Viliam (referee) ; Suchopár, Josef (referee)
Charles University in Prague, Faculty of Pharmacy in Hradec Kralove Department of Social and Clinical Pharmacy Candidate Mgr. Jan Kostriba Supervisor prof. RNDr. Jiri Vlcek, CSc. Title of Doctoral Thesis Analysis of Selected Determinants of Drug Policy in the Czech Republic Introduction: Drug policy as part of health policy is an important factor affecting the efficiency of the health care system. Interest for the government is to realize the consump- tion of drugs in quantities which seeks to optimize the health of the patients. It should be avoided wasting drugs (high consumption of drugs) and deterioration of the health status of the population as a result of inadequate or obsolete treatment (low consumption of medicines). The aim of drug policy is to ensure safe, effective and quality medicines and to ensure optimal and accessible health care to people when required using limited funds. Objectives: The main purpose of this thesis was to analyze the selected determinants of drug policy in the Czech Republic. Attention was especially focused on analyzing the relationships between drug policy, consumption of medicines and health services and the behavior of individuals within the health care system. Other aim of the thesis was to ana- lyze the attitudes and opinions of Czech citizens on selected...
|
|
|
Health Economy and Outcomes Research in the Health Technology Assessment in the Czech Republic
Klimeš, Jiří ; Vlček, Jiří (advisor) ; Foltán, Viliam (referee) ; Švihovec, Jan (referee)
Charles University in Prague Faculty of Pharmacy in Hradec Králové Department of Social and Clinical Pharmacy Candidate Jiří Klimeš, PharmD Supervisor Prof. RNDr. Jiří Vlček, CSc.; MUDr. Tomáš Doležal, PhD (consultant) Title of Doctoral Thesis Health Economy and Outcomes Research in the Health Technology Assessment in the Czech Republic The aim of PhD thesis was to present on practical examples of cost-of-illness (COI), cost- effectiveness (CEA), cost-utility (CUA) and outcomes research analyses their application within current HTA (Health Technology Assessment) process of drug technologies in the Czech Republic. HTA cover complex assessment of medicinal technologies/ interventions in terms of relative effectiveness, safety, health economic aspects (cost-effectiveness and budget impact) and ethical, social and legal aspects. It was presented a methodology of COI studies and their practical application (as the inputs) into CEA, CUA analyses within selected diseases - rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Moreover, it was presented concept of Markov cohort models used in CEA, CUA analyses in area of cardiovascular diseases, post-transplantation care, intensive care medicine and therapy of dementia. Within the CUA, it was interpreted a Probabilistic Sensitivity Analysis in...
|
|
|
Pharmacoeconomic view on the treatment of rheumatic diseases
Petříková, Alena ; Kolář, Jozef (advisor) ; Foltán, Viliam (referee) ; Suchopár, Josef (referee)
Charles University in Prague, Faculty of Pharmacy in Hradec Králové Department of Charles University in Prague, Faculty Of Pharmacy Candidate PharmDr. Alena Petříková Supervisor Doc. RNDr. Jozef Kolář, CsC. Title of Doctoral Thesis Pharmacoeconomic view on the treatment of rheumatic diseases The aim of this thesis is to evaluate the impact of selected rheumatic diseases on health and social insurance, and to investigate the severity and cost of individual items and the distribution of costs among specific subgroups of patients according to type of therapy or disease severity. The methodology used was a Cost-Of-Illness analysis from the societal perspective. Data on treatment, reduction of labour productivity and level of disability were collected through questionnaires (between members of patient organizations or doctors). Indirect costs for all diagnoses were calculated by using the Friction Cost Approach and due to the same methodology can be compared. The dissertation is presenting cost analysis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), psoriasis (Ps) and rheumatoid arthritis (RA). Study cohorts included 1 008 and 509 patients with AS, 256 patients with Ps and 88 patients simultaneously with PsA and 261 patients with RA. Total costs ranged from 94 492 CZK (Ps) to 228 623 CZK...
|
|
|
Drug policy - prices, settlements and participation
Davidová, Jana ; Solich, Jan (advisor) ; Foltán, Viliam (referee) ; Hartlová, Stanislava (referee)
ve Value in Health Participation on drug costs in the elderly in the Czech Republic Davidova, J.; Praznovcova, L.; Vlcek, J. In: Value in Health, Vol. 8 Issue 6 Page 615-A242, Supplement to ISPOR 8th Annual European Congress, Florence, Italy. November 2005 OBJECTIVES: Analysis of participation on drug costs in seniors in the Czech Republic in connection with seniors' social status (e.g. financial, household conditions). METHODS: Quota-sampled questionnaire-based interview with 450 respondents visiting pharmacy; Ratio men:women approximately 1:2; Age 60 years old and elder; 3 regions of the Czech Republic RESULTS: Most of respondents (60 %) live in households with their partners. Respondent's income was retirement pension in 80 %. Its average level was between 5001 and 7499CZK. Respondents used together 1651 medicines on physician's prescription in last four weeks. Overall co-payment for medicines was 31944CZK, e.g. 70CZK per patient. Only 27 % of respondents used fully reimbursed products. Respondents used together 273 OTC drugs in value of 12900CZK, e.g. 29CZK per patient. Average respondents spent on medicines 100CZK in last four weeks, e.g. between 2 and 1.3 % of their income. There were respondents, about 10 %, searching for the level of co-payment in several pharmacies and 8 % of respondents,...
|
guest ::
